PeptideTreatments
Reviewed by Peptide Treatments Medical Advisory Board

GnIH: Research & Evidence

Early-Stage Research

Published research, clinical trial data, and evidence grading for GnIH across studied indications.

Back to GnIH overview

Research Summary

GnIH (RFRP-3 in mammals) was discovered in 2000 in quail hypothalamus and has generated limited academic interest as an inhibitory regulator of the reproductive hormone axis. Human evidence is limited to post-mortem tissue studies confirming RFRP-3 expression in human hypothalamus. There are zero human clinical trials, zero human administration studies, zero safety data, and no pharmaceutical development program. The compound is not commercially available from any peptide vendor or compounding pharmacy. All functional data (LH/FSH inhibition, testosterone suppression, seasonal breeding control) comes from animal models — quail, rat, mouse, and sheep.

Evidence by Indication (2 indications)

Indication Tier Trials Summary
Reproductive hormone regulation Tier D 0 Animal data only — zero human studies
Contraception (theoretical) Tier D 0 Logical extension of mechanism — never studied

Graded using our evidence tier methodology.

Research Gap Score /10

Higher score = larger gap between therapeutic potential and available clinical evidence.

Citations (3 sources)

  1. 1. Discovery and characterization of GnIH Review

    Ubuka T, et al. (2014), Frontiers in Endocrinology

  2. 2. RFRP-3 expression in human hypothalamus Study

    Kiyohiko T, et al. (2009), Endocrinology

  3. 3. Sleep regulation and GnIH-related peptides in mice Study

    Spier AD, de Lecea L (2006), Molecular and Cellular Endocrinology